Drug Manufacturers - Specialty and Generic
Laurus Labs Limited (NSE: LAURUSLABS) gains 5% intraday, tests resistance
Laurus Labs Limited (NSE: LAURUSLABS) stock price moves up 5% intraday to ₹1683.0, testing resistance in the Healthcare sector.
Laurus Labs Limited (LAURUSLABS) tested resistance today, gaining +5% to ₹1683.0 on the NSE. This move follows the stock’s recent trendline shift from bouncing from support to hitting resistance. While the stock is now 0.7% away from the resistance level at ₹1672, it has not yet cleared this threshold. Laurus Labs, a key player in the healthcare sector under drug manufacturers, has seen its stock rise amid broader sector momentum, though today’s move appears to be driven more by technical factors than sector-wide trends.
Technical setup — trendlines & DMA
From a technical perspective, Laurus Labs is currently trading above both its 6-month support trendline at ₹1570.09 and its resistance trendline at ₹1671.98. The stock is 11% above its 50-day moving average (DMA) of ₹1440.9, indicating an extended move. The 50-DMA is also above the 200-DMA of ₹1137.9, signaling a bullish trend. The stock is in the upper third of its 52-week range, up 109% from its 52-week low and 4.5% from its 52-week high, suggesting that a significant portion of the move is already priced in.
Snapshot: ₹1,683.00 on 2026-07-27 (chart frozen at publication)
Fundamentals & business context
On the fundamental side, Laurus Labs presents a mixed picture. With a PE ratio of 97.6 and profit margins at 13.0%, the stock appears richly valued relative to its current earnings, especially given its revenue CAGR of 3.8% over the past five years. The 29.3% institutional ownership suggests that while some investors see value in the company, the valuation may be stretched. There is no specific NSE catalyst today driving the move, indicating that the rise is likely due to technical factors and broader sector momentum rather than new fundamental developments.
Algorithmic scorecard
The algorithmic scorecard for Laurus Labs reflects a technically strong but fundamentally weak profile. The stock’s bullish trend, with the 50-DMA above the 200-DMA, and its strong performance over the past year, contribute to its high technical score. The systematic accumulation, indicated by the volume running 1.64x heavier on up days than down days over the past month, further supports this strength. However, the fundamental weaknesses, such as the slow revenue and profit CAGR, and the overvalued PEG ratio, highlight the risks. The negligible dividend yield and the overvaluation relative to growth also pose concerns for long-term investors.
Company outlook
Management’s forward guidance for Laurus Labs indicates an effective tax rate of around 25% to 26% and a slight increase in gross debt for FY ’27, though debt by EBITDA may be maintained or softened. Key initiatives include the readiness of the commercial scale peptide manufacturing block for validation during Q2 of FY ’27, the start of Phase 1 of the fermentation greenfield site for Laurus Bio by the end of 2026, and the completion of Phase 1 of the formulation facility under the KRKA joint venture in Hyderabad by mid-2027. The company plans to invest around INR3,000 crores in the next two years for growth projects, focusing on capacity creation and advancing commercial peptide manufacturing capabilities.
Get all details on LAURUSLABS — P&L, peers, shareholding and more on TradeAlone.
Drug Manufacturers - Specialty and Generic
IPCA Laboratories Limited (NSE: IPCALAB) extends gains, moves up 10% intraday
IPCA Laboratories Limited (NSE: IPCALAB) stock price moves up 10% intraday to ₹1910.0, extending gains and nearing resistance at ₹1970.
IPCA Laboratories Limited (IPCALAB) extended gains by +10% to ₹1910.0 on the NSE on 17 Aug 2026, as the stock continues to consolidate upwards. This move is driven by the company’s robust financial performance and strategic initiatives, as reflected in its recent corporate announcements and management outlook. IPCALAB operates in the specialty and generic drug manufacturing sector, and today’s move aligns with its strong sector positioning and consistent growth trajectory.
Technical setup — trendlines & DMA
The current trendline structure for IPCALAB shows a 6M support floor at ₹1799.58, which is 5.78% below today’s price. Resistance is approaching at ₹1970, just 3.15% above the current price. The stock is trading at its 50-DMA of ₹1717.2, indicating a key momentum test. With the 50-DMA above the 200-DMA at ₹1542.5, the stock is in a bullish trend. IPCALAB is currently in the upper third of its 52W range, suggesting that a significant portion of its potential upside may already be priced in.
Snapshot: ₹1,910.00 on 2026-08-17 (chart frozen at publication)
Fundamentals & business context
With a PE of 37.9 and profit margins at 11.8%, IPCALAB’s valuation appears stretched relative to its current earnings, though its revenue CAGR of 15.5% and profit CAGR of 34.3% suggest strong growth potential. The 45.2% institutional ownership indicates that smart money has a positive view of the company’s prospects. There was no specific NSE catalyst today, but the stock’s move is consistent with its overall strong fundamental and technical picture.
Algorithmic scorecard
The overall algorithmic scorecard for IPCALAB reflects a balanced but slightly technically weak profile. The strongest signals are the revenue and profit CAGRs, which indicate robust growth, and the very low debt levels, showcasing excellent financial health. These factors suggest a company with solid growth prospects and minimal financial risk. However, the negligible dividend yield and weak momentum in the stock’s price growth over the past month are areas of concern. The low dividend yield may disappoint income-seeking investors, while the weak momentum could indicate a potential pullback or consolidation period ahead.
Company outlook
IPCA Laboratories Limited expects overall growth of around 12% to 13% on a consolidated basis for the current financial year, with an EBITDA margin of approximately 22% to 22.3%. The domestic branded business is guided for around 12% growth, with 1% to 2% coming from new product launches and the rest from price increases and volume. However, increased freight costs by around 25% in the fourth quarter are expected to impact profitability until the Iran-U.S. conflict issue is resolved. The company plans to launch around 18 to 20 products annually in the domestic market, 6 to 8 products in the U.S., and 3 to 4 products in each European and other markets. Ipca’s U.S. subsidiary, Pisgah Labs, is constructing a formulation facility expected to be commissioned in the fourth quarter of the current financial year.
Get all details on IPCALAB — P&L, peers, shareholding and more on TradeAlone.
Drug Manufacturers - Specialty and Generic
IPCA Laboratories Limited (IPCALAB) extends gains by 7% intraday
IPCA Laboratories Limited (IPCALAB) stock moves up 7% intraday to ₹1865.1, extending gains in the Healthcare sector.
IPCA Laboratories Limited (IPCALAB) extended gains by +7% to ₹1865.1 on the NSE today, pushing higher within its consolidating uptrend. The stock is near support at ₹1800, just 3.5% above it, and has not cleared resistance. This move comes after the company informed the Exchange about the Link of Recording for an analysts/institutional investor meet and the voting results from the Annual General Meeting held on August 13, 2026. IPCALAB operates in the specialty and generic drug manufacturing sector, and today’s move appears to be company-specific rather than a sector-wide momentum.
Technical setup — trendlines & DMA
The current trendline structure shows IPCALAB trading above its 6M support trendline at ₹1799.58, which is 3.51% below today’s price. Resistance is at ₹1970.17, with the stock currently 5.63% below this level. The 50-DMA at ₹1717.2 is above the 200-DMA at ₹1542.5, indicating a bullish trend. The stock is trading just above the 50-DMA, suggesting it is either extended or in a recovery phase. Within its 52-week range of ₹1251.6 to ₹1944.9, the stock is in the upper third, implying that a significant portion of the move is already priced in.
Snapshot: ₹1,865.10 on 2026-08-17 (chart frozen at publication)
Fundamentals & business context
With a PE of 37.9 and profit margins at 11.8%, IPCALAB’s valuation appears stretched relative to its current earnings. However, the revenue CAGR of 15.5% and profit CAGR of 34.3% suggest strong growth potential, which may justify the higher PE. The 45.2% institutional ownership indicates that smart money has a positive view of the company’s prospects. There was no specific NSE catalyst today, but the overall growth outlook and strategic plans outlined by management contribute to the stock’s performance.
Algorithmic scorecard
The overall algorithmic scorecard of 82 reflects a balanced view, with strong fundamental and technical signals. The two strongest signals are the revenue CAGR of 15.5% and profit CAGR of 34.3%, indicating robust growth. Additionally, the very low debt level with a D/E ratio of 0.16 points to excellent financial health. On the weaker side, the negligible dividend yield of 0.34% offers little income for investors, and the weak momentum with limited price growth over the past month suggests some caution. These factors collectively paint a picture of a company with strong growth potential but also some risks to consider.
Company outlook
IPCA Laboratories Limited expects overall growth of around 12% to 13% on a consolidated basis for the current financial year, with an EBITDA margin of approximately 22% to 22.3%. The domestic branded business is guided for around 12% growth, with 1% to 2% coming from new product launches and the rest from price increases and volume. However, freight costs have increased by around 25% in the fourth quarter, which is expected to impact profitability until the Iran-U.S. conflict issue is resolved. The company plans to launch around 18 to 20 products in the domestic market annually, with 6 to 8 products in the U.S. and 3 to 4 products in each European and other markets. Ipca’s U.S. subsidiary, Pisgah Labs, is constructing a formulation facility expected to be commissioned in the fourth quarter of the current financial year.
Get all details on IPCALAB — P&L, peers, shareholding and more on TradeAlone.
Drug Manufacturers - Specialty and Generic
Natco Pharma Limited (NATCOPHARM) moves down 6% intraday
Natco Pharma Limited (NATCOPHARM) experiences a 6% intraday decline to ₹892.6, signaling a breakdown in trendline status.
Natco Pharma Limited (NATCOPHARM) fell -6% to ₹892.6 on the NSE on 14 Aug 2026. The stock’s trendline status shifted from a breakdown to approaching resistance, which likely contributed to the decline. Natco Pharma is a specialty and generic drug manufacturer within the healthcare sector. Today’s move appears to be company-specific, as it does not align with broader sector momentum.
Technical setup — trendlines & DMA
The current 6M trendline structure shows a breakdown, with the stock now trading below the 6M support trendline of ₹914.01 by 2.40%. Resistance is at ₹839.43, which the stock has broken above by 5.96%. The 50-DMA at ₹917.5 is above the 200-DMA at ₹949.9, indicating a bearish trend. However, the stock is currently trading above both moving averages, suggesting some recovery. In the 52W range of ₹789.0–₹1226.8, the stock is in the lower third, implying that much of the downside is already priced in.
Snapshot: ₹892.60 on 2026-08-14 (chart frozen at publication)
Fundamentals & business context
With a PE of 12.0, Natco Pharma’s valuation appears reasonable given its strong profit margin of 34.8% and a robust revenue CAGR of 14.8%. The market seems to be pricing in the company’s solid growth trajectory rather than a turnaround. Institutional ownership stands at 12.6%, indicating a cautious but positive view from the smart money. There was no NSE catalyst today that directly influenced the stock’s movement.
Algorithmic scorecard
The overall algorithmic scorecard reflects a balanced view, with strong fundamental indicators offsetting weaker technical signals. Two of the strongest fundamental signals are the excellent profit margin of 34.8% and the undervalued PEG ratio of 0.47, suggesting the stock is cheap relative to its growth. Additionally, the very low debt level with a D/E ratio of 0.04 indicates excellent financial health. On the weaker side, the negligible dividend yield of 0.72% offers little income for investors, and the bearish trend signaled by the 50-DMA being below the 200-DMA suggests ongoing short-term pressure.
Company outlook
Natco Pharma’s management provided forward guidance expecting revenue of INR3,400-3,500 crores and PAT of INR700-750 crores for FY ’27. They anticipate growth in the Brazil subsidiary revenue to INR55-60 million and expect approvals for cancer pipelines in H2 of FY ’26-’27 with earnings impact in ’27-’28. The company aims to reduce earnings volatility by increasing base revenue contribution to 70% and special products to 25-30%. Additionally, Natco Pharma is exploring 1-2 large acquisitions to diversify its portfolio and build a global footprint. The company plans to invest in R&D with an expected expenditure of 7-9% next year and aims for 15-25% compounded growth in earnings from FY ’28 onwards.
Get all details on NATCOPHARM — P&L, peers, shareholding and more on TradeAlone.
-
ARVIND2 days agoArvind Limited (arvind) Inaugurates State-of-the-art Garment Manufacturing Facility in Varanasi
-
COFORGE2 days agoCoforge Limited (NSE: Coforge) Named Leader in Everest Group QE Services for AI Applications and Systems PEAK Matrix® Assessment 2026
-
Consumer Defensive1 day agoLt Foods Limited Launches Campaign for Rozana with Celebrity Chef Ranveer Brar
-
Conglomerates1 day agoDcm Shriram Limited (dcmshriram) Q2 FY27: 22% Revenue Growth at ₹3,977 Crore
-
Healthcare1 day agoSudeep Pharma Limited (sudeepphrm) FDA Approval Enables New Pharma Greenfield Facility Operations
-
E2E1 day agoE2e Networks Limited Plans 5.4 MW Nvidia Blackwell Expansion of India’s AI Factory
-
RAYMONDREL1 day agoRaymond Realty Limited (raymondrel) Secures ₹210 Crore Investment for Ten X Realty West
-
Agricultural Inputs1 day agoAstec Lifesciences Limited (astec) Q2 FY27: Revenue Down, Ebitda Negative